GLP-1 drugs, synthetic versions of a natural hormone, are revolutionizing weight loss and type 2 diabetes treatment. By ...

Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems ...

Ahead of Halloween, the FDA said that certain Zingerman's Candy bars were recalled over the possible presence of undeclared peanuts and cashews. Meanwhile, KFF Health News published the results of its ...

In our image-obsessed culture‭, ‬the pursuit of physical perfection is often mistaken for health‭, ‬fuelling a stream of ...

They found that the automated diabetes GLP-1 prior authorization proportion of all diabetes GLP-1 claims grew by 17.5 percentage points, or 39.6%, from October 2024 to July 2025.

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

New Scripps Research trial will explore the effects of Lilly’s GLP-1 drug on reducing the symptoms of the debilitating ...

Drug giants Novo Nordisk and Pfizer are locked in a fierce $9 billion bidding war for obesity drug developer Metsera. Novo's ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly.

Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward ...

Dow Jones Top Company Headlines at 5 PM ET: Amazon Posts 13% Revenue Jump, Strong Cloud Sales | Apple ... The e-commerce giant said Amazon Web Services is growing at its fastest rate since 2022, ...